Abstract
Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Current Pharmaceutical Biotechnology
Title:Brain Drug Delivery Systems for Neurodegenerative Disorders
Volume: 13 Issue: 12
Author(s): E. Garbayo, E. Ansorena and M.J. Blanco-Prieto
Affiliation:
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Abstract: Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Export Options
About this article
Cite this article as:
Garbayo E., Ansorena E. and Blanco-Prieto M.J., Brain Drug Delivery Systems for Neurodegenerative Disorders, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341761
DOI https://dx.doi.org/10.2174/138920112803341761 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
25th Anniversary Special Issue.
Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chelating Agents for Neurodegenerative Diseases
Current Medicinal Chemistry The Pharmaceutical Potential of Histone Deacetylase Inhibitors
Current Pharmaceutical Design Editorial:Polypharmacology of Natural Products
Mini-Reviews in Organic Chemistry Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
Current Medicinal Chemistry Editorial [Hot Topic: New Insights and Strategies in Treating Inflammation-Related Diseases (Executive Editor: Tz-Chong Chou)]
Current Pharmaceutical Design Synthesis of Indole and Benzimidazole Substituted Novel 16-Arylidene Steroid Derivatives
Letters in Organic Chemistry Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry Neurodegenerative Diseases: A Multidisciplinary Approach
Current Pharmaceutical Design Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research New Therapeutic Strategies for Coeliac Disease: Tissue Transglutaminase as a Target
Current Medicinal Chemistry Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease
Current Alzheimer Research Differential Effects of Nicotine Exposure on the Hippocampus Across Lifespan
Current Neuropharmacology Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology Applications of Exosomes in Targeted Drug Delivery for the Treatment of Parkinson’s Disease: A Review of Recent Advances and Clinical Challenges
Current Topics in Medicinal Chemistry